Skip to main content Start of content

HESA Committee Meeting

Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Minutes of Proceedings

42nd Parliament, 1st Session
Meeting 128
Thursday, December 6, 2018, 8:46 a.m. to 10:49 a.m.
Televised
Presiding
Bill Casey, Chair (Liberal)

Library of Parliament
• Nadia Faucher, Analyst
• Karin Phillips, Analyst
• Marlisa Tiedemann, Analyst
• Hon. Ginette Petitpas Taylor, P.C., M.P., Minister of Health
Department of Health
• Simon Kennedy, Deputy Minister
Canadian Food Inspection Agency
• Paul Glover, President
Canadian Institutes of Health Research
• Michel Perron, Executive Vice-President
Patented Medicine Prices Review Board
• Douglas Clark, Executive Director
Public Health Agency of Canada
• Siddika Mithani, President
• Theresa Tam, Chief Public Health Officer
Pursuant to Standing Order 108(2), the Committee commenced its study of the subject matter of the Supplementary Estimates (A), 2018-19: Votes 1a and 5a under Canadian Food Inspection Agency, Vote 5a under Canadian Institutes of Health Research, Votes 1a and 10a under Department of Health, Vote 1a under Patented Medicine Prices Review Board and Votes 1a and 10a under Public Health Agency of Canada.

The Minister made a statement and, with Simon Kennedy, answered questions.

At 9:48 a.m., the sitting was suspended.

At 9:50 a.m., the sitting resumed.

Simon Kennedy, Siddika Mithani, Michel Perron and Paul Glover answered questions.

At 10:20 a.m., the sitting was suspended.

At 10:24 a.m., the sitting resumed in camera.

Pursuant to Standing Order 108(2) and the motion adopted by the Committee on Wednesday, April 18, 2018, the Committee resumed its study of the barriers to access to treatment and drugs for Canadians affected by rare diseases and disorders.

The Committee proceeded to give additional drafting instructions to the analysts for a report.
Pursuant to Standing Order 108(2) and the motion adopted by the Committee on Tuesday, March 21, 2017, the Committee resumed its study of diabetes strategies in Canada and abroad.

The Committee proceeded to give additional drafting instructions to the analysts for a report.
The Committee proceeded to the consideration of matters related to Committee business.

It was agreed, — That the Committee travel to Winnipeg, Manitoba, and other Canadian cities in 2019 in relation to its study of the impacts of methamphetamine abuse in Canada.

It was agreed, — That the Committee travel to Toronto, Ontario, Vancouver, British Columbia, and other Canadian cities in 2019 in relation to its study of LGBTQ2 health in Canada.

At 10:49 a.m., the Committee adjourned to the call of the Chair.



Marie-Hélène Sauvé
Clerk of the Committee